Effect of marijuana use on outcomes in traumatic brain injury

American Surgeon

Volumn 80, Issue 10, 2014, Pages 979-983

  Nguyen, Brian M ^a   Kim, Dennis ^a   Bricker, Scott ^a   Bongard, Fred ^a   Neville, Angela ^a   Putnam, Brant ^a   Smith, Jennifer ^a   Plurad, David ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TETRAHYDROCANNABINOL; BIOLOGICAL MARKER; DRONABINOL;

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ETHNIC DIFFERENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; RETROSPECTIVE STUDY; SCREENING TEST; SEX RATIO; TOXICITY TESTING; TRAUMATIC BRAIN INJURY; AGED; BRAIN INJURY; CANNABIS SMOKING; COMPARATIVE STUDY; MIDDLE AGED; PROGNOSIS; STATISTICAL MODEL; SUBSTANCE ABUSE; URINE;

ADULT; AGED; BIOLOGICAL MARKERS; BRAIN INJURIES; DRONABINOL; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MARIJUANA SMOKING; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SUBSTANCE ABUSE DETECTION;

EID: 84921752213     PISSN: 00031348     EISSN: 15559823     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Center for Behavioral Health Statistics and Quality. (2012). Guide to DAWN Trend Tables, 2010 Update. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2010.
2. Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 2012;344:e536.
3. Yoles E, Belkin M, Schwartz M. HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy. J Neurotrauma 1996;13:49-57.
4. Brewter ME, Pop E, Foltz RL, et al. Clinical pharmacokinetics of escalating IV doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. Int J Clin Pharmacol Ther 1997;35:361-5.
5. Durmaz R, Ozsandik A, Sahintürk V, et al. Dexanabinol prevents development of vasospasm in the rat femoral artery model. Neurosurg Rev 2008;31:215-23.
6. Shohami E, Gallily R, Mechoulam R, et al. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol 1997;72:169-77.
7. Knoller N, Levi L, Shoshan I, et al. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit Care Med 2002;30:548-54.
8. Maas A, Murry G, Henney H III, et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomized, placebo-controlled, clinical trial. Lancet Neurol 2006;5:38-45.
9. Tomida I, Azuara-Blanco A, House H, et al. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma 2006;15:349-53.
10. Borgelt LM, Franson KL, Nussbaum AM, et al. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy 2013;33:195-209.
11. Ravikoff Allegretti J, Courtwright A, Lucci M, et al. Marijuana use patterns among patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2809-14.
12. Lagbas C, Bazargan-Hejazi S, Shaheen M, et al. Traumatic brain injury related hospitalization and mortality in California. Biomed Res Int 2013;2013:143092.
13. Gowran A, Noonan J, Campbell VA. The multiplicity of action of cannabinoids: implications for treating neurodegeneration. CNS Neurosci Ther 2011;17:637-44.
14. Sagredo O, Pazos MR, Satta V, et al. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. J Neurosci Res 2011;89:1509-18.
15. O'Phelan K, McArthur DL, Chang CW, et al. The impact of substance abuse on mortality in patients with severe traumatic brain injury. J Trauma 2008;65:674-7.
16. Goodwin RS, Darwin WD, Chiang CN, et al. Urinary elimination of 11-nor-9-tetrahydrocannabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol 2008;32:562-9.